Announcement • Oct 18

AXIM Biotechnologies, Inc. Announces Management Changes

AXIM Biotechnologies, Inc. announced that due to the fact that the company's President, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness, on October 9, 2024, the company’s board of directors appointed Catalina Valencia as the Company’s new President. On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness. Acting by written consent in lieu of a meeting, effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy that existed as a result of the death of John W. Huemoeller II. Ms. Catalina Valencia, age 75, is a serial entrepreneur with extensive management experience in biotechnology, telecommunications and hi-tech industries. Ms. Valencia’s legal career began at a prestigious Wall Street law firm followed by a series of senior in-house counsel positions for several fast-growth companies including early stage Genentech. She subsequently focused on managing start-ups and small businesses and supporting them in the development of their businesses and products. She is fluent in Spanish, Italian and Portuguese. Highlights of Ms. Valencia’s legal experience include working in Rio de Janeiro Brazil for Cooley, Godward structuring joint ventures between American and Brazilian companies, at Genentech, Inc. In 2018, Ms. Valencia formed Sapphire Biotech, Inc. whose mission was the detection of early stage breast cancer. In 2020, Sapphire was acquired by AXIM Biotechnologies, Inc. and Ms. Valencia began, and continues, to operate AXIM’s research and development arm. Sapphire subsequently developed for commercial launch the two ophthalmic diagnostics products acquired by AXIM in 2021 for the diagnosis of dry eye disease and allergic conjunctivitis. Ms. Valencia attended college at UCLA where she graduated Magna Cum Laude, Highest Department Honors and obtained her law degree from the University of California, Berkeley Law School. She is the recipient of a Fulbright Fellowship to conduct research in Brazil. Her community service includes serving on the Boards of the California Hispanic Chambers of Commerce, the Mexican and American Solidarity Foundation, the Spanish Speaking Unity Council and the San Ysidro Health Board of Trustees.

AXIM Biotechnologies, Inc. Stock Price

AXIM Share Price Performance

AXIM Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

AXIM Biotechnologies, Inc. Key Details

About AXIM

Recent AXIM News & Updates

AXIM Biotechnologies, Inc. Files Form 15

AXIM Biotechnologies, Inc. announced delayed 10-Q filing

AXIM Biotechnologies, Inc. Announces Management Changes

Recent updates

AXIM Biotechnologies, Inc. Competitors

Matinas BioPharma Holdings

Curis

International Stem Cell

American Films